Oncology
Non-Small Cell Lung Cancer
Clinical Topic Updates Podcast: Targeted Therapy for HER2-Mutant Non–Small Cell Lung Cancer
In recent years, the effective targeting of HER2-mutant non–small cell lung cancer (NSCLC) has become possible, beginning with HER2-targeted ADC therapy and followed by the recent US Food and Drug Administration (FDA) accelerated approvals of 2 TKIs for HER2 TKD-activating mutations. In this podcast, Helena A. Yu, MD, discusses new developments in the treatment of HER2-mutant NSCLC.
Ferrari G, Del Rio B, Novello S, Passiglia F. HER2-altered non-small cell lung cancer: a journey from current approaches to emerging strategies. Cancers (Basel). 2024;16(11):2018. doi:10.3390/cancers16112018
Heymach JV, Popat S, Smit EF, et al. The role of zongertinib, a highly selective tyrosine kinase inhibitor, in targeting HER2-mutant NSCLC: a bench-to-bedside review. Expert Rev Anticancer Ther. Published online February 18, 2026. doi:10.1080/14737140.2026.2623059
Heymach JV, Ruiter G, Ahn MJ, et al; Beamion LUNG-1 Investigators. Zongertinib in previously treated HER2-mutant non–small-cell lung cancer. N Engl J Med. 2025;392(23):2321-2333. doi:10.1056/NEJMoa2503704
Le X, Kim TM, Loong HH, et al; SOHO-01 Investigators. Sevabertinib in advanced HER2-mutant non–small-cell lung cancer. N Engl J Med. 2025;393(18):1819-1832. doi:10.1056/NEJMoa2511065
Li BT, Smit EF, Goto Y, et al; DESTINY-Lung01 Trial Investigators. Trastuzumab deruxtecan in HER2-mutant non–small-cell lung cancer. N Engl J Med. 2022;386(3):241-251. doi:10.1056/NEJMoa2112431
Smit EF, Felip E, Uprety D, et al. Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial. Lancet Oncol. 2024;25(4):439-454. doi:10.1016/S1470-2045(24)00064-0
Explore More in Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
